Current disease status-Recurrent cancer-Metastatic recurrence Posts on Medivizor
Navigation Menu

Current disease status-Recurrent cancer-Metastatic recurrence Posts on Medivizor

What are the outcomes of sipuleucel-T treatment for patients with metastatic castration-resistant prostate cancer?

Posted by on Oct 1, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluated the safety and effectiveness of sipuleucel-T (Provenge) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The authors found that the average survival after sipuleucel-T treatment was 30.7 months and that 13.7% of patients experienced side effects. Some background...

Read More

Searching for patients with advanced prostate cancer to test a new drug combination

Posted by on Mar 16, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 3 trial will evaluate the safety and effectiveness of olaparib (Lynparza) and abiraterone (Zytiga) combination in prostate cancer. The main outcome will be the rate of survival without cancer growing or spreading. The details Prostate cancer (PC) is cancer that originates in the prostate gland. When cancer progresses to a...

Read More

Searching for patients with castration resistant metastatic prostate cancer to test cabazitaxel and abiraterone

Posted by on Dec 10, 2018 in Prostate cancer | 0 comments

In a nutshell This trial is examining the safety and effectiveness of cabazitaxel (Jevtana) with abiraterone acetate (Zytiga) compared to abiraterone acetate alone for metastatic (cancer that has spread) castration-resistant prostate cancer (cancer that is no longer responding to hormone therapy). The main outcome measured will be the...

Read More

Looking for men with castration-resistant prostate cancer to test ipatasertib plus abiraterone/prednisone

Posted by on Dec 5, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study is to determine the effectiveness and safety of ipatasertib (GDC-0068) in combination with abiraterone (Zytiga) and prednisone/prednisolone (Deltasone) in men with metastatic castration-resistant prostate cancer. The main outcome to be measured is time to disease progression. The details Metastatic prostate...

Read More

An analysis of abiraterone plus prednisone for metastatic castration-resistant prostate cancer

Posted by on Nov 8, 2017 in Prostate cancer | 0 comments

In a nutshell This study aimed to determine which patients  benefited most from abiraterone acetate (Zytiga) and prednisone (Deltasone). This study found that overall survival was increased for all patient groups that received this combination.  Some background A main treatment option for prostate cancer is androgen deprivation...

Read More

Searching for patients with HER2 positive metastatic breast cancer to test palbociclib in combination with standard therapy.

Posted by on Oct 30, 2017 in Breast cancer | 0 comments

In a nutshell This phase 3 trial aims to evaluate the effectiveness of palbociclib (Ibrance) in combination with standard treatments for HER2 positive breast cancer. The main outcome to be investigated is progression free survival. This trial is taking place in Alabama, Illinois, Iowa, Nebraska and Oklahoma in the United States.  The details...

Read More

Looking for participants with advanced melanoma to test the effectiveness of a combined immunotherapy

Posted by on Oct 30, 2017 in Melanoma | 0 comments

In a nutshell This phase 2 trial aims to test the effectiveness of the combined treatment of three different immunotherapies. The main outcomes of this trial will be the tumor response to the treatment and the overall survival.  The details Immunotherapies stimulate the immune system to attack and kill cancer cells the way it would a virus or...

Read More

Dabrafenib combined with trametinib is associated with durable responses in metastatic melanoma

Posted by on Jun 28, 2017 in Melanoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of combined treatment with dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF mutated stage 3 or 4 melanoma. Researchers suggested that the combination treatment has durable (3 years or more) results.   Some background Patients with metastatic (spread to...

Read More